Compounders Research Compare

Biomea Fusion, Inc.(BMEA)

Biotechnology · San Carlos, CA

$1.28-0.02 (-1.54%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

San Carlos, CA

37 employees

biomeafusion.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael J. Hitchcock

View full financials

Biomea Fusion (BMEA) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T13:30:47.254Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:30:47.254Z.

Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 92,543,232
Total debt · period ending 2026-06-30: 877,000
Cash · period ending 2026-06-30: 34,824,000
TTM operating EBITDA · period ending 2026-06-30: -57,524,000

FMP input reference: ee881eee59918e8cff759d9372c22030baed04f147f6b571d3011c58a892a573

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BMEA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

BMEA Competitors' EV/EBITDA Ratio

Biomea Fusion, Inc.

Current

Market Cap

$92.54M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

electroCore, Inc.

Market Cap

$92.41M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Conexeu Sciences Inc.

Market Cap

$88.97M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cardiff Oncology, Inc.

Market Cap

$88.63M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ImmuCell Corporation

Market Cap

$88.21M

EV/EBITDA Ratio

14.69x

TTM Avg

15.77x

3Y Avg

20.95x

5Y Avg

32.73x

CareCloud, Inc.

Market Cap

$87.96M

EV/EBITDA Ratio

4.67x

TTM Avg

4.46x

3Y Avg

3.36x

5Y Avg

3.41x

Equillium, Inc.

Market Cap

$87.88M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Anixa Biosciences, Inc.

Market Cap

$99.01M

EV/EBITDA Ratio

N/A

TTM Avg

65.13x

3Y Avg

65.13x

5Y Avg

65.13x

Korro Bio, Inc.

Market Cap

$101.52M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Acrivon Therapeutics, Inc. Common Stock

Market Cap

$85.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Biomea Fusion, Inc. (BMEA)	$92.54M	N/A	N/A	N/A	N/A
electroCore, Inc. (ECOR)vs ›	$92.41M	N/A	N/A	N/A	N/A
Conexeu Sciences Inc. (CNXU)vs ›	$88.97M	N/A	N/A	N/A	N/A
Cardiff Oncology, Inc. (CRDF)vs ›	$88.63M	N/A	N/A	N/A	N/A
ImmuCell Corporation (ICCC)vs ›	$88.21M	14.69x	15.77x	20.95x	32.73x
CareCloud, Inc. (CCLD)vs ›	$87.96M	4.67x	4.46x	3.36x	3.41x
Equillium, Inc. (EQ)vs ›	$87.88M	N/A	N/A	N/A	N/A
Anixa Biosciences, Inc. (ANIX)vs ›	$99.01M	N/A	65.13x	65.13x	65.13x
Korro Bio, Inc. (KRRO)vs ›	$101.52M	N/A	N/A	N/A	N/A
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$85.60M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics